Immunocore Holdings ( (IMCR) ) just unveiled an announcement.
On February 25, 2025, Immunocore Holdings appointed William Pao, M.D., Ph.D., as a Class II director, bringing his extensive experience from roles at Revelio Therapeutics and Pfizer. In 2024, Immunocore reported $310 million in KIMMTRAK sales, launched in 14 new countries, and continued its clinical pipeline advancements, including Phase 3 trials for melanoma and PRAME portfolio developments, supported by a strong cash position of $820.4 million.
More about Immunocore Holdings
Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing transformative immunomodulating medicines to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. The company is known for its lead product, KIMMTRAK (tebentafusp), which is approved in 39 countries for metastatic uveal melanoma and continues to expand globally.
YTD Price Performance: 0.57%
Average Trading Volume: 254,313
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.5B
Learn more about IMCR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com